Securing a partner to serve as an extension of Janssen’s Biotherapeutics Development API-Large Molecule team was essential to reducing both risk and the time needed for delivery of critical clinical supplies.
3D printing allows drug companies to not only boost efficacy and adherence but also contribute to their brand longevity by expanding and capturing market share with other dosage form options.
By applying remote monitoring solutions, advanced modeling, and optimization of manufacturing processes, Industry 4.0 offers improved process reliability and product quality through unlimited possibilities of connecting machines and data.
Cory Card, Principal Scientist at GE, discusses not just ideas shared at a recent industry symposium on raw material variability control, but, most importantly, where to go from here.
Harness the collective knowledge of your organization and partners.
Using its Supplier Relationship Excellence (SRE) program, Amgen opened the lines of communication with suppliers and created a feedback loop where data can be shared to better understand operational performance.
Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
Pharma and biotech companies have invested heavily in externalized research, development, and manufacturing in recent years – but their methods of sharing critical data are still rarely fit for purpose.
Brady Haggstrom, IDBS, looks at the changing landscape of drug development and delivery, which is more and more outsourced nowadays, and how technology can help protect sensitive research data.
Antibodies continue to dominate. Analyzing the strategies employed by successful players in the field could provide invaluable lessons for those hoping to enter it.